EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

Pneumomycoses in Clinical Practice (Review))

P.F. Dudka, D.V. Dobrianskyi, Y.M. Bondarenko, I.P. Tarchenko

Tuberculosis, Lung Diseases, HIV Infection · 11.05.2026 · (2) · 96-100

DOI: 10.30978/tb2026-2-96 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tuberculosis, Lung Diseases, HIV Infection, online erschienen am 11.05.2026. Verfasst von P.F. Dudka und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective — to analyse the features of the clinical course and modern diagnostics of pneumomycoses. Materials and methods. A systematic review and content analysis of scientific publications indexed in the international scientometric databases PubMed, Web of Science and Google Scholar were conducted. The search covered the period from 2022 to 2025. Results and discussion. This study provides a detailed systematisation of current understanding of the clinical manifestations and diagnostic strategies for pulmonary mycoses. The main focus is on the three most common nosologies: invasive aspergillosis, actinomycosis (as a specific bacterial process that mimics mycosis) and histoplasmosis. The role of imaging methods, particularly high-resolution CT and PET-CT, as well as the diagnostic value of bronchoalveolar lavage (BAL) and transthoracic biopsy, is detailed. The advantages of molecular genetic testing (PCR, NGS) and the determination of serological markers (galactomannan, β-D-glucan) for early pathogen identification are highlighted. Establishing a timely diagnosis of fungal lung infection can be challenging due to the absence of specific symptoms and the frequent presence of a concomitant infectious process, which can lead to a significant delay in the initiation of aetiological treatment. Conclusions. The diagnosis of pulmonary mycoses should be based on the identification of risk factors, assessment of imaging findings (CT, PET-CT), analysis of histological data and indicators of non-invasive biomarkers (β-D-glucan, galactomannan). Untimely diagnosed pneumomycoses can lead to dissemination, cavitation, progression of respiratory failure and mortality. Considering the increasing resistance of fungal infections to antifungal agents, there is an urgent need to implement modern treatment standards for pulmonary mycoses in clinical practice.

Zitieren

APA

Dudka, P., Dobrianskyi, D., Bondarenko, Y., & Tarchenko, I. (2026). Pneumomycoses in Clinical Practice (Review)). Tuberculosis, Lung Diseases, HIV Infection, 96-100. https://doi.org/10.30978/tb2026-2-96

Vancouver

Dudka P, Dobrianskyi D, Bondarenko Y, Tarchenko I. Pneumomycoses in Clinical Practice (Review)). Tuberculosis, Lung Diseases, HIV Infection. 2026:96-100. doi:10.30978/tb2026-2-96

BibTeX
@article{Dudka2026,
  author = {Dudka, P.F. and Dobrianskyi, D.V. and Bondarenko, Y.M. and Tarchenko, I.P.},
  title = {Pneumomycoses in Clinical Practice (Review))},
  journal = {Tuberculosis, Lung Diseases, HIV Infection},
  year = {2026},
  number = {2},
  pages = {96--100},
  doi = {10.30978/tb2026-2-96}
}
Kostenlos starten →